List of Therapeutic Companies in Wisconsin - 21

Proprietary products for the prevention and treatment of multi-drug resistant Gram negative bacterial infections.

BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry.

We harness our team’s decades of experience in the biology of the serotonergic system to understand the effect specific receptors have on our body. From there, we create new and modify existing molecules in order to reduce unwanted side effects and accentuate positive therapeutic properties. This new generation of highly targeted serotonergic drugs will be able to reach specific patient populations that the compounds of today cannot.

Centrose is a biopharmaceutical company that develops and commercializes small molecular drug therapeutics for the treatment of cancer.

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition resulting in a reduction of oxygen that reaches the blood stream and vital organs. Few effective therapeutic modalities exist to treat ARDS, leading to a high mortality rate. ENDECE designed NDC-1308 to reduce the ability of SARS-CoV-2 / COVID-19 to replicate within the pulmonary system, and reduce inflammation.

Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes. Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin. Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.

Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer’s disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives. The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies. Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.

FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in respiratory diseases.

Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.

Developing anti-inflammatory drugs that modify Protease-Activated Receptor signaling (PARmodulins). Parmodulins are small molecules that can selectively block certain aspects of inflammation while promoting anti-inflammatory signals mediated by protease-activated receptor 1 (PAR1).

Invenra offers flexible partnering options to meet diverse antibody discovery needs, from rapid, focused bispecific antibody discovery to comprehensive, collaborative development partnerships. Our new rapid bispecific discovery service, powered by the B-Body® Bispecific Platform, identifies bispecific lead panels within four months through functional screening of over 250 bispecific combinations, using mAbs derived from 90 parallel discovery screens. For those seeking a strategic, partnered approach, Invenra provides tailored support across all stages of discovery, from custom antigen design and assay development to in-depth biological analysis. This dual offering allows us to address a broad spectrum of objectives, from expedited project timelines for focused discovery services to fully integrated solutions for collaborative development partnerships.

ioGenetics

JangoBio is developing regenerative therapies to reverse hormone imbalances associated with aging and thereby mitigate the risk of developing a wide range of age-related diseases. Pharmaceutical treatments, such as hormone supplementation, do not address the underlying loss of function, and can have significant side effects.

At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer, and customized radiopharmaceutical development services. Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies to meet this important healthcare need. We routinely produce the therapeutic radioisotope copper-67 (Cu-67) and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. At NorthStar, we prioritize professional growth of our employees. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to providing our employees with fulfilling work experiences and valuable career development opportunities.

Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.

Health tech startup developing artificial intelligence tools for ear exams.

Plumb Pharmaceuticals Inc. is a company dedicated to solving problems of medication compliance with extended-release formulations of FDA-approved drugs. Plumb Pharmaceuticals has developed a drug delivery platform for super-extended-release medications based on proprietary liposome preparation and loading. The company's lipid nanoparticle technology offers stimulants for treating ADHD, anti-HIV drugs, antibiotics, antipsychotics, and cancer chemotherapy agents.

Seeking To Redefine What Is Possible® Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis’ drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company’s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.

Varigen Biosciences Corporation is using metagenomics tools to investigatemicrobial diversity and develop natural products.

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.

Zurex Pharma is a specialty pharma and medical technology company based in Middleton, Wisconsin.